The next strongest RPMI-sensitive hits were deguelin, a reported PI3K inhibitor shown to impair cell growth across several cancer types (88), and apilimod, a putative phosphatidylinositol 3-phosphate 5-kinase (PIKFYVE) inhibitor that has been tested in lymphoma patients (89, 90). Here, PIKFYVE is linked to cancer.